ArticleFrontiers in medicine2025
A mitochondrial ferroptosis-related gene signature predicts prognosis and immune landscape in colon cancer.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhanced Collagen Prolyl 4-Hydroxylase Activity and Expression Promote Cancer Progression via Both Canonical and Non-Canonical Mechanisms.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colon cancer is a highly aggressive gastrointestinal malignancy with significant global health implications. Although mitochondrial ferroptosis-related genes have been implicated in colon cancer progression, their prognostic significance remains inadequately understood. Methods: We conducted a comprehensive analysis of the expression patterns and prognostic value of mitochondrial ferroptosis-related genes in patients with colon cancer, utilizing data from the TCGA and GEO databases. A prognostic risk model was established, followed by evaluations of the tumor microenvironment (TME), immune cell infiltration, tumor mutation burden (TMB), and predicted drug sensitivity. P4HA1, recognized as an important mitochondrial ferroptosis-associated gene, was selected for functional characterization using Results: Four key mitochondrial ferroptosis-associated genes-PDSS2, GRSF1, SLC39A8, and P4HA1-were identified. A nomogram combining the risk score and pTNM stage was constructed to predict patient outcomes. Immune microenvironment analysis revealed distinct differences in immune cell infiltration between the high- and low-risk groups. The risk score was significantly correlated with the expression of TME-related genes and immune checkpoint molecules, suggesting a more immunosuppressive microenvironment in high-risk patients. Furthermore, integrating the risk score with TMB enhanced the accuracy of survival prediction. Silencing P4HA1 markedly reduces the proliferative and migratory abilities of colorectal cancer cells Conclusion: This mitochondrial ferroptosis-based risk model represents a promising prognostic biomarker and may offer valuable insights for personalized treatment strategies in colon cancer management. P4HA1 facilitates the advancement of colorectal cancer, while its suppression diminishes the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.